BTIG Research Maintains Buy on Regeneron Pharmaceuticals, But Lowers Price Target From $520 to $480 On The Heels Of Monday's Announcement That Nesvacumab Didn't Meet Clinical Study Endpoints And Won't Enter Phase 3 Development
Hal Lindon